Host-Cell Transformation Markers for Assessing Cervical Cancer Risk in High-Risk HPV Infections
Lucas Wu
21/11/26
Human papillomavirus, or HPV, is a common viral infection, but only a small proportion of high-risk infections progress to cervical intraepithelial neoplasia or invasive cervical cancer. Although HPV persistence, viral oncogene activity, and transformation biomarkers have been studied extensively, these factors are often examined separately, creating a need for a synthesis of how they interact during disease progression. This study examined HPV disease progression, the cellular proteins and molecular pathways involved in transformation, and the factors that influence whether infection clears or becomes persistent. We hypothesized that host-cell transformation markers may improve cervical cancer risk assessment by identifying molecular and cellular changes associated with persistent high-risk HPV infection and cervical precancer. A secondary literature-based analysis was conducted using peer-reviewed studies identified through Google Scholar and PubMed, along with information from reputable health institutions including the Centers for Disease Control and Prevention and the National Cancer Institute. The findings showed that persistent high-risk HPV infection is closely associated with cervical precancer and cancer, while CIN 2 may regress, persist, or progress and CIN 3 carries a greater risk of invasive disease. E6 and E7 were consistently identified as central drivers of transformation through disruption of p53, pRB, apoptosis, cell-cycle control, and related signaling pathways. p16INK4a/Ki-67 dual staining and E6/E7 mRNA or oncoprotein testing appeared to provide more information about active cellular transformation and existing high-grade cervical lesions compared with HPV DNA testing alone. Immune suppression, HIV infection, and long-term immunosuppressive treatment were also associated with reduced HPV control. These findings support further investigation of combined viral and host-cell biomarkers for improving cervical cancer risk assessment, although additional longitudinal studies are needed to establish their ability to predict future disease progression.
